ACRS - Aclaris Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
8,844
10,091
1,683
0
0
Cost of Revenue
6,815
6,850
1,207
-
0
Gross Profit
2,029
3,241
476
-
0
Operating Expenses
Research Development
74,861
63,009
39,790
33,476
15,339
Selling General and Administrative
76,295
74,146
33,109
15,091
5,328
Total Operating Expenses
151,156
137,155
72,899
48,567
20,667
Operating Income or Loss
-149,127
-133,914
-72,423
-48,567
-20,667
Interest Expense
-
-
-
-
-
Total Other Income/Expenses Net
-19,158
1,176
2,070
488
0
Income Before Tax
-168,285
-132,738
-70,353
-48,079
-20,563
Income Tax Expense
-
0
-1,830
-
-
Income from Continuing Operations
-168,285
-132,738
-68,523
-48,079
-20,563
Net Income
-181,311
-132,738
-68,523
-48,079
-20,563
Net Income available to common shareholders
-181,311
-132,738
-68,523
-48,079
-23,129
Reported EPS
Basic
-
-4.03
-2.44
-2.25
-3.79
Diluted
-
-4.03
-2.44
-2.25
-3.79
Weighted average shares outstanding
Basic
-
32,910
28,102
21,416
6,107
Diluted
-
32,910
28,102
21,416
6,107
EBITDA
-
-132,035
-72,021
-48,447
-20,667